The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery.
Millotti
Gioconda
G
University of Innsbruck, Pharmaceutical Technology, Innrain 52c, Innsbruck, 6020 Austria.
Perera
Glen
G
Vigl
Claudia
C
Pickl
Karin
K
Sinner
Frank Michael
FM
Bernkop-Schnürch
Andreas
A
D000268:Adhesiveness; D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D018938:Caco-2 Cells; D048271:Chitosan / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000633:toxicity; D004337:Drug Carriers / Q000737:chemistry / Q000633:toxicity; D016503:Drug Delivery Systems; D004355:Drug Stability; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D008297:Male; D053758:Nanoparticles; D010316:Particle Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D013438:Sulfhydryl Compounds / Q000737:chemistry* / Q000633:toxicity
D004337:Drug Carriers; D007328:Insulin; D013438:Sulfhydryl Compounds; C559281:chitosan-6-mercaptonicotinic acid; D048271:Chitosan